News

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

A University of Calgary research team, partnered with Biosenta Inc., has developed a method to transform limestone into a long-lasting antimicrobial nanoparticle. This new "shell and core" technology has a durable active ingredient, calcium hydroxide, and has been proven effective against various harmful pathogens. Potential applications include enhancing concrete, paint for healthcare settings, and coatings for food packaging and high-touch surfaces.

Kris Hans shares how Biosenta is tackling the antimicrobial health crisis at the source, and why this work matters now more than ever.

Biosenta Inc. Achieves Major Breakthroughs in Bench Scale Production and Innovative Input Viability.

Biosenta announces significant advancements at its state-of-the-art bench scale production facility.

Biosenta has been making the innovative strides in the realm of antimicrobial biotechnology.

Biosenta Inc. announces licensing agreement

Biosenta announces technological and operational advancements with successful construction and operation of a bench scale production plant.

Biosenta announces a pivotal discovery revealed that Tri-Filler™ effectively sterilizes a wide range of microorganisms.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta Inc. announces further advances in research and development of Tri-Filler™

UoC professor taking about a solution fighting a drug-resistant fungus that has become a big issue for hospitals in the U.S. and Canada.

Biosenta Inc. announces further advances in research and development of the Tri-Filler™ particle.

Biosenta Inc. announces that it has ceased negotiations with Voran Group Ventures Ltd.

Chelsey Reschke is one of 47 Canadians attending the G20 Young Entrepreneurs’ Alliance summit in Hamburg from Oct. 27 to 28.

Biosenta Inc. has signed an MOU with Voran Group Ventures Ltd. for the commercialization of Biosenta’s Tri-Filler® antimicrobial products.

University of Calgary very encouraging anti-bacterial Biosenta particles for construction industry

This partnership enables the University team to research nanoparticles for use as antimicrobial filler in commercial construction materials.